decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2002 / AB-02-100
Subscribe or sign in to view the full article.
Article Overview
This Medicare program memorandum addresses policy for erythropoietin furnished under the ESRD dialysis benefit and explains the related contractor review approach, implementation timing, and referenced national coverage process. It is relevant to dialysis providers, Medicare contractors, and compliance teams that track program memoranda affecting review procedures and coverage administration.
Why This Topic Matters
It clarifies a temporary Medicare policy change affecting how certain ESRD dialysis-related EPO claims are reviewed, which can influence provider documentation and contractor oversight.
Article Sections
-
Transmittal AB-02-100
Introduces the program memorandum, its date, subject, and administrative context within Medicare guidance.
-
Modification of Medicare Policy for Erythropoietin (EPO)
Summarizes the policy update for EPO claims under the ESRD dialysis benefit and the background leading to the change.
-
Review approach and contractor oversight
Describes the general review framework for claims, including post-payment review considerations and contractor monitoring activities.
-
Applicability, contacts, and implementation
Explains the scope of the instructions, references to related administrative contacts, and the effective and discard dates for the memorandum.
What You Will Learn
- The scope of the Medicare policy update for ESRD-related EPO claims
- How the memorandum frames review and oversight responsibilities
- Which services the instructions apply to and which are excluded
- The administrative timing and implementation status of the memorandum
Who Should Read This
- Medicare contractors
- Dialysis providers
- ESRD facilities
- Medical coders and compliance staff
- Revenue cycle and audit teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com